Clinical Trial Update: Study to Demonstrate Equivalence of Formoterol 12 and 24 µg Delivered Via Two Types of Single Dose Dry Powder Inhalers (Concept1 and Aerolizer) [Phase 2]

View source ↗

Summary

Phase 2 trial update comparing two doses (12 vs 24 mcg) of formoterol delivered by two dry powder inhalers to assess equivalence; study completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Asthma

Drugs mentioned

• Formoterol (formoterol)

Snippet

Sponsor: Novartis | Conditions: Asthma | Phase 2 | Status: COMPLETED